Details of the Drug Reposition

General Information of This Drug (ID: DM6RUKX)

Drug Name
BVT.2733   DM6RUKX
Synonyms CHEMBL553071; AC1OCFOV; 376641-65-5; SCHEMBL5692696; MolPort-042-665-756; 3-chloro-2-methyl-N-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide hydrochloride
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Systemic lupus erythematosus DISI1SZ7 4A40.0 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Myasthenia gravis DISELRCI 8C6Y Phase 2 [1]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-insulin dependent diabetes DISK1O5Z 5A11 Investigative [2]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 2003 Nov;144(11):4755-62.